At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
In this study, researchers want to find the best dose of XmAb819 to treat kidney cancer. The people in this study have clear cell renal cell cancer that keeps growing or came back after standard treatments.
- A Phase 3 Study Assessing Dara-VCD Chemotherapy Alone or With a Stem Cell Transplant for People With Newly Diagnosed AL Amyloidosis
Full Title A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis (S2213) (CIRB)
Purpose
Researchers are comparing combination chemotherapy alone or with a stem cell transplant for people with amyloid light chain (AL) amyloidosis. The people in this study have newly diagnosed AL amyloidosis. The chemotherapy includes daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD).
If you join this study, you will be randomly assigned to get one of these treatments:
- Dara-VCD alone.
- Dara-VCD followed by a stem cell transplant with melphalan. Giving melphalan before a stem cell transplant helps kill cancer cells and makes room for new blood-forming cells to grow.
A stem cell transplant with melphalan after Dara-VCD may kill more cancer cells in people with newly diagnosed AL amyloidosis.
Who Can Join
To join this study, there are a few conditions. You must:
- Have newly diagnosed AL amyloidosis.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Heather Landau’s office at 646-608-3740.
Protocol
25-107Phase
Phase III (phase 3)Investigator
Co-Investigators
Locations
ClinicalTrials.gov ID
NCT06022939ClinicalTrials.gov
-
Researchers want to find the best dose of FOG-001 to use in people with advanced cancer. This study focuses on people who have colorectal and other digestive cancers that spread and keep growing after treatment.
- A Phase 1/2 Study of Belantamab Mafodotin/Dexamethasone Alone or With Iberdomide to Treat Persistent Multiple Myeloma
Full Title A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination with Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma (A062101) (CIRB)
Purpose
Researchers are assessing the iberdomide with belantamab mafodotin and dexamethasone in people with multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing even with treatment.
Multiple myeloma cells have a protein on their surface called BCMA, which allows them to survive and grow. Belantamab mafodotin attaches to BCMA, which may cause myeloma cells to become damaged and die. Iberdomide is an immunotherapy that may promote changes in the immune system and may interfere with cancer growth.
If you join this study, you will be randomly assigned to get one of these treatments:
- Belantamab mafodotin and dexamethasone plus iberdomide
- Belantamab mafodotin and dexamethasone
Belantamab mafodotin is given intravenously (by vein), and iberdomide and dexamethasone are taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have multiple myeloma that came back or keeps growing despite at least two regimens of treatment. Prior treatment may not have included belantamab mafodotin, iberdomide, or a donated stem cell transplant.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Saad Usmani’s office at 646-608-4165.
Protocol
24-373Phase
Phase I/II (phases 1 and 2 combined)Disease Status
Newly Diagnosed & Relapsed/RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06232044ClinicalTrials.gov
-
Researchers are comparing treatment with doxorubicin chemotherapy and pembrolizumab immunotherapy to doxorubicin alone for advanced sarcoma. The people in this study have undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma. Their cancers have metastasized (spread) or are inoperable (cannot be taken out with surgery).
- A Study of Cord Blood Transplantation in Children and Young Adults with Blood Cancers and Non-Cancerous Blood Disorders
Full Title Cord Blood Transplantation in Children and Young Adults with Hematologic Malignancies and Non-Malignant Disorders
Purpose
The transplantation of stem cells from umbilical cord blood is a treatment for some blood cancers and non-cancerous blood or metabolic disorders. Patients routinely receive high doses of chemotherapy and sometimes radiation before receiving the stem cells to help make room in the bone marrow for new blood stem cells to grow, prevent the body from rejecting the transplanted cells, and help kill any abnormal blood cells in the body. However, the combination of these treatments can have serious side effects.
Researchers are doing this study to find out whether a combination of the chemotherapy drugs clofarabine, fludarabine, and busulfan (without radiation) is a safe and effective treatment for children and young adults receiving cord blood transplants for blood cancers or non-cancerous blood or metabolic disorders. These three drugs are given intravenously (by vein).
Who Can Join
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a blood cancer or non-cancerous blood disorder and be candidates for umbilical cord transplantation. Examples of blood cancers include acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), advanced myelodysplasia (MDS), chronic myelogenous leukemia (CML), myeloproliferative disorders, and non-Hodgkin and Hodgkin lymphoma. Examples of non-cancerous disorders include inherited metabolic diseases, Hurler syndrome, Hunter disease, Sly syndrome, alpha-mannosidosis, X-ALD (X-linked adrenoleukodystrophy), osteopetrosis, metachromatic leukodystrophy, globoid cell leukodystrophy, bone marrow failure syndromes, and diseases like HLH (hemophagocytic lymphohistiocytosis) caused by a compromised immune system.
- This study is for patients age 21 and younger.
For more information about this study and to inquire about eligibility, please contact 1-833-MSK-KIDS.
Protocol
20-480Phase
Phase II (phase 2)Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT04644016ClinicalTrials.gov
-
Doctors routinely use intensity-modulated radiation therapy (IMRT) after surgery to treat squamous cell carcinoma (cancer) of the tongue. IMRT delivers radiation directly to cancer cells from different angles by changing the radiation beam into multiple smaller beams. By targeting the tumor more precisely, IMRT reduces radiation damage to healthy tissue.
-
Researchers want to see if a single radiation therapy dose can limit the growth of colorectal cancer liver metastases. The people in this study have colorectal cancer that has metastasized (spread) to the liver. The treatment is called high-dose stereotactic body radiation therapy (SBRT).
-
Researchers want to see if giving NALIRIFOX chemotherapy with high-dose radiation therapy and capecitabine before surgery helps people with pancreatic cancer. The people in this study have pancreatic cancer that involves major blood vessels but has not spread to other organs. The study includes people with pancreatic cancer that may or may not be removable ("borderline resectable" or "locally advanced").
-
Researchers are comparing pembrolizumab given after surgery for head and neck cancer with the usual treatment. The usual therapy includes chemotherapy and radiation therapy. The people in this study have head and neck cancer that came back or is a new primary cancer.